市場調査レポート

商品コード

オピオイド鎮痛薬市場の評価：製品タイプ・用途・投与経路・流通チャネル・地域別の機会および予測 (2017-2031年)

Opioid Analgesics Market Assessment, By Product Type, By Application, By Route of Administration, By Distribution Channel, By Region, Opportunities and Forecast, 2017-2031F

出版日: 2024年11月20日
発行: Market Xcel - Markets and Data
ページ情報: 英文 227 Pages
納期: 3～5営業日

カスタマイズ可能

価格

PDF & Excel Printable (Single User License)

USD 4,500 646,065円

レポートPDFを1名の方がご利用頂けるライセンスです。レポートPDFのパスワード保護はありません。PDF内のテキスト等のコピー＆ペーストは可能です。印刷は無制限で可能です。Excelのデータがライセンスに含まれています。

PDF & Excel Printable (Corporate License)

USD 5,700 818,349円

レポートPDFを企業の１カ国の拠点のすべての方がご利用頂けるライセンスです。レポートPDFのパスワード保護はありません。PDF内のテキスト等のコピー＆ペーストは可能ですが、企業内部での利用に限定されます。ご利用に際しては、あらかじめ出版社の許諾を得る必要があります。詳細はお問合せください。印刷は可能です。Excelのデータがライセンスに含まれています。

PDF & Excel Printable (Custom Research License)

USD 8,200 1,177,274円

レポートPDFを企業の１カ国の拠点のすべての方がご利用頂けるライセンスです。レポートPDFのパスワード保護はありません。PDF内のテキスト等のコピー＆ペーストは可能です。印刷は無制限で可能です。Excelのデータがライセンスに含まれています。アナリストアワー100時間が含まれており、レポートのカスタマイズなどにご利用いただけます。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=143.57円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

世界のオピオイド鎮痛薬の市場規模は、2023年の452億1,000万米ドルから、予測期間中はCAGR 4.03%で推移し、2031年には620億2,000万米ドルに成長すると予測されています。

オピオイド鎮痛薬の市場需要は、慢性疼痛の治療において非オピオイド薬や理学療法が有効でない場合の多剤併用による疼痛に対して、予測期間中に拡大すると予想されています。市場で入手可能なさまざまな治療オプションの迅速な作用発現と高い有効性が、オピオイド鎮痛薬の需要を高めています。

また、がん、関節炎、腰痛、心臓病などの慢性疼痛疾患の有病率の増加もオピオイド鎮痛薬の需要増加につながっています。また、オピオイドの使用にまつわる安全性の懸念を解消し、乱用抑止効果のある製剤技術を駆使した新しい製剤の進歩も市場の成長を後押ししています。過去数年にわたり、薬物の誤用は世界の健康上の大きな問題として浮上しています。疼痛緩和を目的としたオピオイドの処方が大幅に増加する中で、その乱用率も高まっています。薬物中毒と処方オピオイドの過剰摂取の抑制は、乱用防止製剤を用いて効果的に管理することができます。FDAは、オピオイド乱用問題に対処するため、処方オピオイドの乱用防止製剤 (ADF) の開発を推進しています。

当レポートでは、世界のオピオイド鎮痛薬の市場を調査し、市場の定義と概要、市場規模の推移・予測、各種区分・地域/主要国別の詳細分析、産業構造、市場成長への影響因子の分析、ケーススタディ、競合情勢、主要企業のプロファイルなどをまとめています。

市場リーダー上位5社の競合マトリックス
上位5社のSWOT分析
上位10社の情勢
- Pfizer Inc.
- Johnson & Johnson Services, Inc.
- Teva Pharmaceuticals Industries Ltd.
- Endo Pharmaceuticals Inc.
- Sun Pharmaceuticals Industries Ltd.
- Bayer AG
- Abbott Laboratories
- Purdue Pharma L.P.
- Hikma Pharmaceuticals PLC.
- Sanofi S.A.

第22章戦略的提言

第23章当社について・免責事項

図表

List of Tables

Table 1. Pricing Analysis of Products from Key Players
Table 2. Competition Matrix of Top 5 Market Leaders
Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

Figure 1. Global Opioid Analgesics Market, By Value, In USD Billion, 2017-2031F
Figure 2. Global Opioid Analgesics Market Share (%), By Product Type, 2017-2031F
Figure 3. Global Opioid Analgesics Market Share (%), By Application, 2017-2031F
Figure 4. Global Opioid Analgesics Market Share (%), By Route of Administration, 2017-2031F
Figure 5. Global Opioid Analgesics Market Share (%), By Distribution, 2017-2031F
Figure 6. Global Opioid Analgesics Market Share (%), By Region, 2017-2031F
Figure 7. North America Opioid Analgesics Market, By Value, In USD Billion, 2017-2031F
Figure 8. North America Opioid Analgesics Market Share (%), By Product Type, 2017-2031F
Figure 9. North America Opioid Analgesics Market Share (%), By Application, 2017-2031F
Figure 10. North America Opioid Analgesics Market Share (%), By Route of Administration, 2017-2031F
Figure 11. North America Opioid Analgesics Market Share (%), By Distribution, 2017-2031F
Figure 12. North America Opioid Analgesics Market Share (%), By Country, 2017-2031F
Figure 13. United States Opioid Analgesics Market, By Value, In USD Billion, 2017-2031F
Figure 14. United States Opioid Analgesics Market Share (%), By Product Type, 2017-2031F
Figure 15. United States Opioid Analgesics Market Share (%), By Application, 2017-2031F
Figure 16. United States Opioid Analgesics Market Share (%), By Route of Administration, 2017-2031F
Figure 17. United States Opioid Analgesics Market Share (%), By Distribution, 2017-2031F
Figure 18. Canada Opioid Analgesics Market, By Value, In USD Billion, 2017-2031F
Figure 19. Canada Opioid Analgesics Market Share (%), By Product Type, 2017-2031F
Figure 20. Canada Opioid Analgesics Market Share (%), By Application, 2017-2031F
Figure 21. Canada Opioid Analgesics Market Share (%), By Route of Administration, 2017-2031F
Figure 22. Canada Opioid Analgesics Market Share (%), By Distribution, 2017-2031F
Figure 23. Mexico Opioid Analgesics Market, By Value, In USD Billion, 2017-2031F
Figure 24. Mexico Opioid Analgesics Market Share (%), By Product Type, 2017-2031F
Figure 25. Mexico Opioid Analgesics Market Share (%), By Application, 2017-2031F
Figure 26. Mexico Opioid Analgesics Market Share (%), By Route of Administration, 2017-2031F
Figure 27. Mexico Opioid Analgesics Market Share (%), By Distribution, 2017-2031F
Figure 28. Europe Opioid Analgesics Market, By Value, In USD Billion, 2017-2031F
Figure 29. Europe Opioid Analgesics Market Share (%), By Product Type, 2017-2031F
Figure 30. Europe Opioid Analgesics Market Share (%), By Application, 2017-2031F
Figure 31. Europe Opioid Analgesics Market Share (%), By Route of Administration, 2017-2031F
Figure 32. Europe Opioid Analgesics Market Share (%), By Distribution, 2017-2031F
Figure 33. Europe Opioid Analgesics Market Share (%), By Country, 2017-2031F
Figure 34. Germany Opioid Analgesics Market, By Value, In USD Billion, 2017-2031F
Figure 35. Germany Opioid Analgesics Market Share (%), By Product Type, 2017-2031F
Figure 36. Germany Opioid Analgesics Market Share (%), By Application, 2017-2031F
Figure 37. Germany Opioid Analgesics Market Share (%), By Route of Administration, 2017-2031F
Figure 38. Germany Opioid Analgesics Market Share (%), By Distribution, 2017-2031F
Figure 39. France Opioid Analgesics Market, By Value, In USD Billion, 2017-2031F
Figure 40. France Opioid Analgesics Market Share (%), By Product Type, 2017-2031F
Figure 41. France Opioid Analgesics Market Share (%), By Application, 2017-2031F
Figure 42. France Opioid Analgesics Market Share (%), By Route of Administration, 2017-2031F
Figure 43. France Opioid Analgesics Market Share (%), By Distribution, 2017-2031F
Figure 44. Italy Opioid Analgesics Market, By Value, In USD Billion, 2017-2031F
Figure 45. Italy Opioid Analgesics Market Share (%), By Product Type, 2017-2031F
Figure 46. Italy Opioid Analgesics Market Share (%), By Application, 2017-2031F
Figure 47. Italy Opioid Analgesics Market Share (%), By Route of Administration, 2017-2031F
Figure 48. Italy Opioid Analgesics Market Share (%), By Distribution, 2017-2031F
Figure 49. United Kingdom Opioid Analgesics Market, By Value, In USD Billion, 2017-2031F
Figure 50. United Kingdom Opioid Analgesics Market Share (%), By Product Type, 2017-2031F
Figure 51. United Kingdom Opioid Analgesics Market Share (%), By Application, 2017-2031F
Figure 52. United Kingdom Opioid Analgesics Market Share (%), By Route of Administration, 2017-2031F
Figure 53. United Kingdom Opioid Analgesics Market Share (%), By Distribution, 2017-2031F
Figure 54. Russia Opioid Analgesics Market, By Value, In USD Billion, 2017-2031F
Figure 55. Russia Opioid Analgesics Market Share (%), By Product Type, 2017-2031F
Figure 56. Russia Opioid Analgesics Market Share (%), By Application, 2017-2031F
Figure 57. Russia Opioid Analgesics Market Share (%), By Route of Administration, 2017-2031F
Figure 58. Russia Opioid Analgesics Market Share (%), By Distribution, 2017-2031F
Figure 59. Netherlands Opioid Analgesics Market, By Value, In USD Billion, 2017-2031F
Figure 60. Netherlands Opioid Analgesics Market Share (%), By Product Type, 2017-2031F
Figure 61. Netherlands Opioid Analgesics Market Share (%), By Application, 2017-2031F
Figure 62. Netherlands Opioid Analgesics Market Share (%), By Route of Administration, 2017-2031F
Figure 63. Netherlands Opioid Analgesics Market Share (%), By Distribution, 2017-2031F
Figure 64. Spain Opioid Analgesics Market, By Value, In USD Billion, 2017-2031F
Figure 65. Spain Opioid Analgesics Market Share (%), By Product Type, 2017-2031F
Figure 66. Spain Opioid Analgesics Market Share (%), By Application, 2017-2031F
Figure 67. Spain Opioid Analgesics Market Share (%), By Route of Administration, 2017-2031F
Figure 68. Spain Opioid Analgesics Market Share (%), By Distribution, 2017-2031F
Figure 69. Turkey Opioid Analgesics Market, By Value, In USD Billion, 2017-2031F
Figure 70. Turkey Opioid Analgesics Market Share (%), By Product Type, 2017-2031F
Figure 71. Turkey Opioid Analgesics Market Share (%), By Application, 2017-2031F
Figure 72. Turkey Opioid Analgesics Market Share (%), By Route of Administration, 2017-2031F
Figure 73. Turkey Opioid Analgesics Market Share (%), By Distribution, 2017-2031F
Figure 74. Poland Opioid Analgesics Market, By Value, In USD Billion, 2017-2031F
Figure 75. Poland Opioid Analgesics Market Share (%), By Product Type, 2017-2031F
Figure 76. Poland Opioid Analgesics Market Share (%), By Application, 2017-2031F
Figure 77. Poland Opioid Analgesics Market Share (%), By Route of Administration, 2017-2031F
Figure 78. Poland Opioid Analgesics Market Share (%), By Distribution, 2017-2031F
Figure 79. South America Opioid Analgesics Market, By Value, In USD Billion, 2017-2031F
Figure 80. South America Opioid Analgesics Market Share (%), By Product Type, 2017-2031F
Figure 81. South America Opioid Analgesics Market Share (%), By Application, 2017-2031F
Figure 82. South America Opioid Analgesics Market Share (%), By Route of Administration, 2017-2031F
Figure 83. South America Opioid Analgesics Market Share (%), By Distribution, 2017-2031F
Figure 84. South America Opioid Analgesics Market Share (%), By Country, 2017-2031F
Figure 85. Brazil Opioid Analgesics Market, By Value, In USD Billion, 2017-2031F
Figure 86. Brazil Opioid Analgesics Market Share (%), By Product Type, 2017-2031F
Figure 87. Brazil Opioid Analgesics Market Share (%), By Application, 2017-2031F
Figure 88. Brazil Opioid Analgesics Market Share (%), By Route of Administration, 2017-2031F
Figure 89. Brazil Opioid Analgesics Market Share (%), By Distribution, 2017-2031F
Figure 90. Argentina Opioid Analgesics Market, By Value, In USD Billion, 2017-2031F
Figure 91. Argentina Opioid Analgesics Market Share (%), By Product Type, 2017-2031F
Figure 92. Argentina Opioid Analgesics Market Share (%), By Application, 2017-2031F
Figure 93. Argentina Opioid Analgesics Market Share (%), By Route of Administration, 2017-2031F
Figure 94. Argentina Opioid Analgesics Market Share (%), By Distribution, 2017-2031F
Figure 95. Asia-Pacific Opioid Analgesics Market, By Value, In USD Billion, 2017-2031F
Figure 96. Asia-Pacific Opioid Analgesics Market Share (%), By Product Type, 2017-2031F
Figure 97. Asia-Pacific Opioid Analgesics Market Share (%), By Application, 2017-2031F
Figure 98. Asia-Pacific Opioid Analgesics Market Share (%), By Route of Administration, 2017-2031F
Figure 99. Asia-Pacific Opioid Analgesics Market Share (%), By Distribution, 2017-2031F
Figure 100. Asia-Pacific Opioid Analgesics Market Share (%), By Country, 2017-2031F
Figure 101. India Opioid Analgesics Market, By Value, In USD Billion, 2017-2031F
Figure 102. India Opioid Analgesics Market Share (%), By Product Type, 2017-2031F
Figure 103. India Opioid Analgesics Market Share (%), By Application, 2017-2031F
Figure 104. India Opioid Analgesics Market Share (%), By Route of Administration, 2017-2031F
Figure 105. India Opioid Analgesics Market Share (%), By Distribution, 2017-2031F
Figure 106. China Opioid Analgesics Market, By Value, In USD Billion, 2017-2031F
Figure 107. China Opioid Analgesics Market Share (%), By Product Type, 2017-2031F
Figure 108. China Opioid Analgesics Market Share (%), By Application, 2017-2031F
Figure 109. China Opioid Analgesics Market Share (%), By Route of Administration, 2017-2031F
Figure 110. China Opioid Analgesics Market Share (%), By Distribution, 2017-2031F
Figure 111. Japan Opioid Analgesics Market, By Value, In USD Billion, 2017-2031F
Figure 112. Japan Opioid Analgesics Market Share (%), By Product Type, 2017-2031F
Figure 113. Japan Opioid Analgesics Market Share (%), By Application, 2017-2031F
Figure 114. Japan Opioid Analgesics Market Share (%), By Route of Administration, 2017-2031F
Figure 115. Japan Opioid Analgesics Market Share (%), By Distribution, 2017-2031F
Figure 116. Australia Opioid Analgesics Market, By Value, In USD Billion, 2017-2031F
Figure 117. Australia Opioid Analgesics Market Share (%), By Product Type, 2017-2031F
Figure 118. Australia Opioid Analgesics Market Share (%), By Application, 2017-2031F
Figure 119. Australia Opioid Analgesics Market Share (%), By Route of Administration, 2017-2031F
Figure 120. Australia Opioid Analgesics Market Share (%), By Distribution, 2017-2031F
Figure 121. Vietnam Opioid Analgesics Market, By Value, In USD Billion, 2017-2031F
Figure 122. Vietnam Opioid Analgesics Market Share (%), By Product Type, 2017-2031F
Figure 123. Vietnam Opioid Analgesics Market Share (%), By Application, 2017-2031F
Figure 124. Vietnam Opioid Analgesics Market Share (%), By Route of Administration, 2017-2031F
Figure 125. Vietnam Opioid Analgesics Market Share (%), By Distribution, 2017-2031F
Figure 126. South Korea Opioid Analgesics Market, By Value, In USD Billion, 2017-2031F
Figure 127. South Korea Opioid Analgesics Market Share (%), By Product Type, 2017-2031F
Figure 128. South Korea Opioid Analgesics Market Share (%), By Application, 2017-2031F
Figure 129. South Korea Opioid Analgesics Market Share (%), By Route of Administration, 2017-2031F
Figure 130. South Korea Opioid Analgesics Market Share (%), By Distribution, 2017-2031F
Figure 131. Indonesia Opioid Analgesics Market, By Value, In USD Billion, 2017-2031F
Figure 132. Indonesia Opioid Analgesics Market Share (%), By Product Type, 2017-2031F
Figure 133. Indonesia Opioid Analgesics Market Share (%), By Application, 2017-2031F
Figure 134. Indonesia Opioid Analgesics Market Share (%), By Route of Administration, 2017-2031F
Figure 135. Indonesia Opioid Analgesics Market Share (%), By Distribution, 2017-2031F
Figure 136. Philippines Opioid Analgesics Market, By Value, In USD Billion, 2017-2031F
Figure 137. Philippines Opioid Analgesics Market Share (%), By Product Type, 2017-2031F
Figure 138. Philippines Opioid Analgesics Market Share (%), By Application, 2017-2031F
Figure 139. Philippines Opioid Analgesics Market Share (%), By Route of Administration, 2017-2031F
Figure 140. Philippines Opioid Analgesics Market Share (%), By Distribution, 2017-2031F
Figure 141. Middle East & Africa Opioid Analgesics Market, By Value, In USD Billion, 2017-2031F
Figure 142. Middle East & Africa Opioid Analgesics Market Share (%), By Product Type, 2017-2031F
Figure 143. Middle East & Africa Opioid Analgesics Market Share (%), By Application, 2017-2031F
Figure 144. Middle East & Africa Opioid Analgesics Market Share (%), By Route of Administration, 2017-2031F
Figure 145. Middle East & Africa Opioid Analgesics Market Share (%), By Distribution, 2017-2031F
Figure 146. Middle East & Africa Opioid Analgesics Market Share (%), By Country, 2017-2031F
Figure 147. Saudi Arabia Opioid Analgesics Market, By Value, In USD Billion, 2017-2031F
Figure 148. Saudi Arabia Opioid Analgesics Market Share (%), By Product Type, 2017-2031F
Figure 149. Saudi Arabia Opioid Analgesics Market Share (%), By Application, 2017-2031F
Figure 150. Saudi Arabia Opioid Analgesics Market Share (%), By Route of Administration, 2017-2031F
Figure 151. Saudi Arabia Opioid Analgesics Market Share (%), By Distribution, 2017-2031F
Figure 152. UAE Opioid Analgesics Market, By Value, In USD Billion, 2017-2031F
Figure 153. UAE Opioid Analgesics Market Share (%), By Product Type, 2017-2031F
Figure 154. UAE Opioid Analgesics Market Share (%), By Application, 2017-2031F
Figure 155. UAE Opioid Analgesics Market Share (%), By Route of Administration, 2017-2031F
Figure 156. UAE Opioid Analgesics Market Share (%), By Distribution, 2017-2031F
Figure 157. South Africa Opioid Analgesics Market, By Value, In USD Billion, 2017-2031F
Figure 158. South Africa Opioid Analgesics Market Share (%), By Product Type, 2017-2031F
Figure 159. South Africa Opioid Analgesics Market Share (%), By Application, 2017-2031F
Figure 160. South Africa Opioid Analgesics Market Share (%), By Route of Administration, 2017-2031F
Figure 161. South Africa Opioid Analgesics Market Share (%), By Distribution, 2017-2031F
Figure 162. By Product Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 163. By Application Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 164. By Route of Administration Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 165. By Distribution Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 166. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023

Product Code: MX12267

Global opioid analgesics market is projected to witness a CAGR of 4.03% during the forecast period 2024-2031, growing from USD 45.21 billion in 2023 to USD 62.02 billion in 2031. The market demand for opioid analgesic pharmaceutical products is anticipated to thrive in the forecast period for multimodal pain when non-opioid drugs or physical therapy is ineffective for treating chronic pain issues. The quick onset of action and high efficacy of various treatment options available in the market are increasing the demand for opioid analgesics.

Also, an increase in the prevalence of chronic pain conditions such as cancer, arthritis, and lower back pain, heart disease has led to an increase in demand for opioid analgesics in the market. Advancements in new formulations by resolving safety concerns around the use of opioids and abuse-deterrent formulation technology are boosting the growth of the market. Over the past few years, drug misuse has emerged as a major global health concern. The prescription of opioids for pain relief has increased substantially, and so has the rate of abuse for them. Controlling drug addiction and prescription opioid overdoses can be effectively managed using abuse-deterrent formations. The FDA is pushing for the development of abuse-deterrent formulations (ADFs) for prescription opioids in an effort to address the opioid abuse problem. The government acknowledges that while abuse-deterrent opioids are a step toward potentially less abusive medicines, they are neither abuse nor addiction-proof. For instance, In February 2024, Hikma Pharmaceuticals PLC announced the launch of Fentanyl Citrate Injection, USP 25mcg/0.5mL and 50mcg/mL. As noted by requirements, it is used for anesthesia periods, premedication, induction, and maintenance in the immediate postoperative period. The injection is also used as an adjunct to narcotic analgesia in general or regional anesthesia.

Increasing Prevalence of Cancer to Boost the Market

Chronic pain is present in 20% to 50% of cancer patients. About 80% of advanced-stage cancer patients have moderate to severe pain. One meta-analysis of pooled data from 52 studies found that more than half of the participants reported pain. Cancer pain and pain flares are more likely to occur in younger patients than older patients. Advances in understanding the biological mechanisms of cancer-related pain have led to better-targeted and more effective use of opioids. The global burden of cancer has grown recently, so research into finding new therapies and improving patient outcomes has increased. The increase in the incidence of cancer directly relates to a greater need for pain management strategies that are efficacious. The major driver for the opioid analgesic market is increased research and development initiatives being taken for the treatment of cancer. It is a reality that an increase in knowledge of cancer-related pain is substantially increasing the use of opioid analgesics for pain management. This trend underlines the role of pain relief in cancer care, highlighting a need for providers to balance opioid use with strategies for minimizing misuse and dependence, thus leading to safer and more effective patient care. Researchers are increasingly focusing on developing new therapies and evaluating their efficacy and safety.

Increasing Prevalence of Chronic Pain

The growth of the opioid market is driven by the increasing prevalence of chronic pain, which is affecting millions of individuals globally with the condition such as chronic conditions, including arthritis, fibromyalgia, and neuropathic pain, are increasingly becoming common, and patients are seeking effective pain management solutions to enhance their quality of life. With the increasing prevalence of chronic pain, coupled with an aging population more likely to suffer from this condition, healthcare providers turn to opioids as the first line of treatment. Continued research and development for opioid formulations is also being undertaken to optimize their efficacy with minimal side effects, therefore fueling additional growth in the market. The ongoing development of opioid formulations continues toward improved efficacy but with reduced potential side effects and related dependency risks. These advances address the dual considerations of efficacy and safety in pain relief, patients and providers towards the management of chronic pain with opioids as part of treatment.

In August 2022, Adalvo Limited announced that the company had acquired its first branded product, Onsolis, after finalizing a deal with a leading US-based specialty pharmaceutical company. The brand is an opioid analgesic used in the management of persistent breakthrough pain in cancer patients who are already receiving and tolerant to opioid therapy for their underlying cancer pain. The ongoing development of opioid formulations continues toward improved efficacy but with reduced potential side effects and related dependency risks. These advances address the dual considerations of efficacy and safety in pain relief, nudging patients and providers toward the management of chronic pain with opioids as part of treatment.

Codeine Segment to Dominate the Opioid Analgesics Market

The codeine market is likely to lead in the opioid analgesics market in view of its widespread use and application in clinical conditions for pain management. Codeine is a naturally occurring opioid and is most often preferred as an alternative due to its effective analgesic properties along with relatively lower severity of side effects compared with stronger opioids, making it a popular medicine for the treatment of mild to moderate pain, especially in outpatient settings. In addition, the availability of codeine in several formulations involving combination products with acetaminophen or aspirin makes it more attractive to prescribers and patients. The increasing prevalence of chronic pain disorders and the demand for better pain relief interventions will keep supporting this segment. Continued studies and development of codeine as the best therapeutic agent ensure that the opioid analgesics market will be dominated by codeine. There are several studies that are currently undergoing on Codeine, for instance, the National Superiority Clinical Trial to assess the combination of fixed dosage of Dipyrone and Codeine comparing the isolated use of components in the control of moderate to severe pain after open pelvic-abdominal surgery.

North America Dominates the Opioid Analgesics Market

North America dominates the opioid analgesics markets due to the high prevalence of chronic pain, neuropathic pain, and postoperative surgical pain. Chronic pain is a condition that affects the daily life of many adults in the United States. According to the Centers for Disease Control and Prevention (CDC), almost 21% of the U.S. population, i.e., 51.6 million adults' population, is affected by chronic pain, and 6.9% (17.1 million people) experienced severe chronic pain (i.e., chronic pain that causes significant limitation of daily activities), with a higher prevalence among non-Hispanic American Indians or Alaskans. According to CDC reports that analyzed data from the National Health Interview Survey, chronic pain lasts for at least three months and usually affects the ability to function and work. In contrast, high-impact chronic pain occurs when chronic pain significantly reduces the activities of daily living. Chronic pain is a major public health problem in the United States. The healthcare cost of chronic pain in America is estimated at USD 635 billion per year, according to a JAMA Network Open article.

Future Market Scenario (2024-2031F)

In the opioid analgesic market over the past 10 years, considerable fluctuations have been observed mainly due to the increase in opioid crisis and regulatory control. Nevertheless, future scenarios will be formed through the development of healthcare practice, regulating the framework and achievements in pain management. Pharmaceutical companies are investing in developing abuse-deterrent formulations. These innovations can restore trust between doctors and patients and increase market acceptance. The opioid analgesics market is expected to remain stable, with growth potential in certain areas due to innovation and a growing understanding of pain management. Companies that focus on developing safer opioid formulations and alternative pain management solutions are likely to see growth, which is anticipated to drive the opioid analgesics market. Collaboration with regulators and healthcare providers is key to shaping a responsible future for the opioid analgesics market.

Key Players Landscape and Outlook

The multimodal pain management opioid analgesics market is highly dynamic, with several players like Pfizer Inc., Johnson & Johnson Services, Inc., Teva Pharmaceuticals Industries Ltd., Endo Pharmaceuticals Inc., Sun Pharmaceuticals Industries Ltd., Bayer AG, Abbott Laboratories, Purdue Pharma L.P., Hikma Pharmaceuticals PLC., Sanofi S.A. Corporation Opioid Analgesics. Significant market activities have been reported in recent times, including distribution agreements and acquisitions alongside several product launches. In May 2023 Trevena Inc. a biopharmaceutical company, announced that its partner, Jiangsu Nhwa Pharmaceutical Co., Ltd., a China-based pharmaceutical company, has received approval from China's National Medical Products Administration (NMPA) for Olinvyk (oliceridine). Olinvyk is an opioid agonist indicated to manage pain severe enough to require an intravenous opioid analgesic in adult patients whose alternative treatments are inadequate.

In April 2023, Rusan Pharma Ltd. submitted a proposal to the commission for approval to manufacture and market methadone oral solution 1 mg/ml, as well as an application for a BA/BE research and clinical trial exemption. Methadone oral solution 1 mg/ml is already approved product. But this firm is required to submit BA/BE study protocol for further review by the committee.

1. Project Scope and Definitions

2. Research Methodology

3. Executive Summary

4. Global Opioid Analgesics Market Outlook, 2017-2031F

4.1. Market Size Analysis & Forecast
- 4.1.1. By Value
4.2. Market Share Analysis & Forecast
- 4.2.1. By Products Type
  - 4.2.1.1. Codeine
  - 4.2.1.2. Morphine
  - 4.2.1.3. Oxycodone
  - 4.2.1.4. Hydrocodone
  - 4.2.1.5. Methadone
  - 4.2.1.6. Meperidine
  - 4.2.1.7. Fentanyl
  - 4.2.1.8. Hydromorphone
  - 4.2.1.9. Oxymorphone
  - 4.2.1.10. Dextromethorphan
  - 4.2.1.11. Tramadol
  - 4.2.1.12. Others
- 4.2.2. By Application
  - 4.2.2.1. Chronic Pain
  - 4.2.2.2. Acute Pain
- 4.2.3. By Route of Administration
  - 4.2.3.1. Oral
  - 4.2.3.2. Injectable
  - 4.2.3.3. Others
- 4.2.4. By Distribution
  - 4.2.4.1. Hospital Pharmacy
  - 4.2.4.2. Retail Pharmacy
  - 4.2.4.3. Others
- 4.2.5. By Region
  - 4.2.5.1. North America
  - 4.2.5.2. Europe
  - 4.2.5.3. Asia-Pacific
  - 4.2.5.4. South America
  - 4.2.5.5. Middle East and Africa
- 4.2.6. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2023)
4.3. Market Map Analysis, 2023
- 4.3.1. By Product Type
- 4.3.2. By Application
- 4.3.3. By Route of Administration
- 4.3.4. By Distribution
- 4.3.5. By Region

5. North Opioid Analgesics Market Outlook, 2017-2031F*

5.1. Market Size Analysis & Forecast
- 5.1.1. By Value
5.2. Market Share Analysis & Forecast
- 5.2.1. By Products Type
  - 5.2.1.1. Codeine
  - 5.2.1.2. Morphine
  - 5.2.1.3. Oxycodone
  - 5.2.1.4. Hydrocodone
  - 5.2.1.5. Methadone
  - 5.2.1.6. Meperidine
  - 5.2.1.7. Fentanyl
  - 5.2.1.8. Hydromorphone
  - 5.2.1.9. Oxymorphone
  - 5.2.1.10. Dextromethorphan
  - 5.2.1.11. Tramadol
  - 5.2.1.12. Others
- 5.2.2. By Application
  - 5.2.2.1. Chronic Pain
  - 5.2.2.2. Acute Pain
- 5.2.3. By Route of Administration
  - 5.2.3.1. Oral
  - 5.2.3.2. Injectable
  - 5.2.3.3. Others
- 5.2.4. By Distribution
  - 5.2.4.1. Hospital Pharmacy
  - 5.2.4.2. Retail Pharmacy
  - 5.2.4.3. Others
- 5.2.5. By Country Share
  - 5.2.5.1. United States
  - 5.2.5.2. Canada
  - 5.2.5.3. Mexico
5.3. Country Market Assessment
- 5.3.1. United States Opioids Analgesics Market Outlook, 2017-2031F*
  - 5.3.1.1. Market Size Analysis & Forecast
    - 5.3.1.1.1. By Value
  - 5.3.1.2. Market Share Analysis & Forecast
    - 5.3.1.2.1. By Product type
      - 5.3.1.2.1.1. Codeine
      - 5.3.1.2.1.2. Morphine
      - 5.3.1.2.1.3. Oxycodone
      - 5.3.1.2.1.4. Hydrocodone
      - 5.3.1.2.1.5. Methadone
      - 5.3.1.2.1.6. Meperidine
      - 5.3.1.2.1.7. Fentanyl
      - 5.3.1.2.1.8. Hydromorphone
      - 5.3.1.2.1.9. Oxymorphone
      - 5.3.1.2.1.10. Dextromethorphan
      - 5.3.1.2.1.11. Tramadol
      - 5.3.1.2.1.12. Others
    - 5.3.1.2.2. By Application
      - 5.3.1.2.2.1. Chronic Pain
      - 5.3.1.2.2.2. Acute Pain
    - 5.3.1.2.3. By Route of Administration
      - 5.3.1.2.3.1. Oral
      - 5.3.1.2.3.2. Injectable
      - 5.3.1.2.3.3. Others
    - 5.3.1.2.4. By Distribution
      - 5.3.1.2.4.1. Hospitals Pharmacy
      - 5.3.1.2.4.2. Retail Pharmacy
      - 5.3.1.2.4.3. Others
- 5.3.2. Canada
- 5.3.3. Mexico

All segments will be provided for all regions and countries covered

6. Europe Opioid Analgesics Market Outlook, 2017-2031F

6.1. Germany
6.2. France
6.3. Italy
6.4. United Kingdom
6.5. Russia
6.6. Netherlands
6.7. Spain
6.8. Poland

7. Asia-Pacific Opioids Analgesics Market Outlook, 2017-2031F

7.1. India
7.2. China
7.3. Japan
7.4. Australia
7.5. Vietnam
7.6. South Korea
7.7. Indonesia
7.8. Philippines

8. South America Opioid Analgesics Market Outlook, 2017-2031F

8.1. Brazil
8.2. Argentina

9. Middle East and Africa Opioid Analgesics Market Outlook, 2017-2031F

9.1. Saudi Arabia
9.2. UAE
9.3. South Africa
9.4. Israel

10. Demand Supply Analysis

11. Import and Export Analysis

12. Value Chain Analysis

13. Porter's Five Forces Analysis

14. PESTLE Analysis

15. Pricing Analysis

16. Market Dynamics

16.1. Market Drivers
16.2. Market Challenges

17. Market Trends and Developments

18. Regulatory Framework and Innovation

18.1. Clinical Trials
18.2. Regulatory Approvals

19. Patent Landscape

20. Case Studies

21. Competitive Landscape

21.1. Competition Matrix of Top 5 Market Leaders
21.2. SWOT Analysis for Top 5 Players
21.3. Key Players Landscape for Top 10 Market Players
- 21.3.1. Pfizer Inc.
  - 21.3.1.1. Company Details
  - 21.3.1.2. Key Management Personnel
  - 21.3.1.3. Products and Services
  - 21.3.1.4. Financials (As Reported)
  - 21.3.1.5. Key Market Focus and Geographical Presence
  - 21.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisitions
- 21.3.2. Johnson & Johnson Services, Inc.
- 21.3.3. Teva Pharmaceuticals Industries Ltd.
- 21.3.4. Endo Pharmaceuticals Inc.
- 21.3.5. Sun Pharmaceuticals Industries Ltd.
- 21.3.6. Bayer AG
- 21.3.7. Abbott Laboratories
- 21.3.8. Purdue Pharma L.P.
- 21.3.9. Hikma Pharmaceuticals PLC.
- 21.3.10. Sanofi S.A.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

オピオイド鎮痛薬市場の評価：製品タイプ・用途・投与経路・流通チャネル・地域別の機会および予測 (2017-2031年)

Opioid Analgesics Market Assessment, By Product Type, By Application, By Route of Administration, By Distribution Channel, By Region, Opportunities and Forecast, 2017-2031F

目次

第1章 プロジェクトの範囲と定義

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 世界のオピオイド鎮痛薬市場の展望

第5章 北米のオピオイド鎮痛薬市場の展望

第6章 欧州のオピオイド鎮痛薬市場の展望

第7章 アジア太平洋のオピオイド鎮痛薬市場の展望

第8章 南米のオピオイド鎮痛薬市場の展望

第9章 中東・アフリカのオピオイド鎮痛薬市場の展望

第10章 需給分析

第11章 輸出入分析

第12章 バリューチェーン分析

第13章 ポーターのファイブフォース分析

第14章 PESTLE分析

第15章 価格分析

第16章 市場力学

第17章 市場の動向・展開

第18章 法規制の枠組み・イノベーション

第19章 特許情勢

第20章 ケーススタディ

第21章 競合情勢

第22章 戦略的提言

第23章 当社について・免責事項

List of Tables

List of Figures

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Executive Summary

4. Global Opioid Analgesics Market Outlook, 2017-2031F

5. North Opioid Analgesics Market Outlook, 2017-2031F*

6. Europe Opioid Analgesics Market Outlook, 2017-2031F

7. Asia-Pacific Opioids Analgesics Market Outlook, 2017-2031F

8. South America Opioid Analgesics Market Outlook, 2017-2031F

9. Middle East and Africa Opioid Analgesics Market Outlook, 2017-2031F

10. Demand Supply Analysis

11. Import and Export Analysis

12. Value Chain Analysis

13. Porter's Five Forces Analysis

14. PESTLE Analysis

15. Pricing Analysis

16. Market Dynamics

17. Market Trends and Developments

18. Regulatory Framework and Innovation

19. Patent Landscape

20. Case Studies

21. Competitive Landscape

22. Strategic Recommendations

23. About Us and Disclaimer

第1章プロジェクトの範囲と定義

第2章調査手法

第3章エグゼクティブサマリー

第4章世界のオピオイド鎮痛薬市場の展望

第5章北米のオピオイド鎮痛薬市場の展望

第6章欧州のオピオイド鎮痛薬市場の展望

第7章アジア太平洋のオピオイド鎮痛薬市場の展望

第8章南米のオピオイド鎮痛薬市場の展望

第9章中東・アフリカのオピオイド鎮痛薬市場の展望

第10章需給分析

第11章輸出入分析

第12章バリューチェーン分析

第13章ポーターのファイブフォース分析

第15章価格分析

第16章市場力学

第17章市場の動向・展開

第18章法規制の枠組み・イノベーション

第19章特許情勢

第20章ケーススタディ

第21章競合情勢

第22章戦略的提言

第23章当社について・免責事項